Ratings Enfusion, Inc.

Equities

ENFN

US2928121043

Market Closed - Nyse Other stock markets 04:00:07 2024-05-03 pm EDT			5-day change	1st Jan Change
9.555 ^USD	+0.37%		+1.59%	-1.34%

Mar. 14	Enfusion Shares Slip After Short-Seller Spruce Point Warns of 'Financial Restatement Risk'	MT
Mar. 13	BofA Securities Adjusts Price Target on Enfusion to $9 From $8, Maintains Underperform Rating	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
The company's profit outlook over the next few years is a strong asset.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Sales forecast by analysts have been recently revised upwards.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 77.72 times its estimated earnings per share for the ongoing year.
With an enterprise value anticipated at 3.96 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Software

	1st Jan change	Capi.	ESG Refinitiv
ENFUSION, INC.	-1.34%	865M	-
SYNOPSYS INC.	+4.28%	79.84B	B
CADENCE DESIGN SYSTEMS, INC.	+3.40%	75.23B	B+
DASSAULT SYSTÈMES SE	-16.54%	51.63B	B+
PALANTIR TECHNOLOGIES INC.	+35.88%	50.22B	D+
ATLASSIAN CORPORATION	-22.85%	47.78B	B-
THE TRADE DESK, INC.	+23.11%	43.07B	D+
SEA LIMITED	+64.59%	36.75B	D+
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-9.36%	24.41B	C+
ROBLOX CORPORATION	-14.17%	23.89B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes